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Summary: Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene strongly predispose to
development of gastro-intestinal tumors. Central to the tumorigenic events in APC mutant cells is the uncontrolled
stabilization and transcriptional activation of the protein b-catenin. Many questions remain as to how APC controls b-
catenin degradation. Remarkably, the large C-terminal region of APC, which spans over 2000 amino acids and includes
critical regions in downregulating b-catenin, is predicted to be natively unfolded. Here we discuss how this uncommonly
large disordered region may help to coordinate the multiple cellular functions of APC. Recently, a significant number of
germline and somatic missense mutations in the central region of APC were linked to tumorigenesis in the colon as well
as extra-intestinal tissues. We classify and localize all currently known missense mutations in the APC structure. The
molecular basis by which these mutations interfere with the function of APC remains unresolved. We propose several
mechanisms by which cancer-related missense mutations in the large disordered domain of APC may interfere with
tumor suppressor activity. Insight in the underlying molecular events will be invaluable in the development of novel
strategies to counter dysregulated Wnt signaling by APC mutations in cancer.
Introduction
Adenomatous polyposis coli (APC) is a key tumor sup-
pressor gene that acts as a gatekeeper of intestinal epithe-
lial homeostasis by restraining cytoplasmic cellular levels
of b-catenin, the central activator of transcription in the
Wnt signaling pathway. At the molecular level, APC co-
scaffolds a multiprotein destruction complex, composed
of the tumor suppressor Axin and the serine-threonine
kinases GSK3b and CK1, which promotes the phosphory-
lation and subsequent ubiquitin-mediated degradation of
b-catenin [1]. A Wnt-induced signal at the cell surface
impedes the function of the APC-Axin complex, leading
to the stabilization and nuclear import of b-catenin, fol-
lowed by the formation of nuclear b-catenin/TCF com-
plexes that activate target gene transcription [2,3].
Besides regulating proliferation and differentiation
through Wnt/b-catenin signaling, APC controls multiple
b-catenin-independent fundamental cellular processes.
These include cell adhesion and migration, organization
of the cytoskeleton, spindle formation and chromosome
segregation [4,5]. The crucial role of APC in fundamental
developmental cellular processes is illustrated by the
embryonic lethality of homozygous Apc-knock-out muta-
tions [6-8]. In this review, we focus on how the remark-
able lack of structure in the large central domain of APC
may facilitate its tumor suppressor function in the Wnt/
b-catenin cascade. Furthermore, by classification and
localization of known cancer-related APC missense
mutations, we uncover different mutational spectra of
germline and somatic missense mutations along the APC
protein sequence, suggesting variation in functional rele-
vance and mechanisms. We discuss how these missense
mutations in the large unstructured region of APC may
predispose to cancer.
The large central domain of APC contains multiple
domains that control Wnt signaling
APC is a 312 kDa protein composed of 2843 amino acid
residues. It carries multiple designated segments with
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any medium, provided the original work is properly cited.which it coordinates its multiple cellular functions (Fig-
ure 1A). The large central region of APC, spanning resi-
dues L1021-D2059, has been implicated in the
downregulation of b-catenin [9,10]. It contains four 15aa
repeat and seven 20aa repeat segments involved in b-
catenin binding [11-13]. The 15aa repeat region also
binds the transcriptional co-repressor CtBP1 and CtBP2,
which prevents nuclear b-catenin activity and facilitates
APC oligomerization and [14-16]. Interspersed with the
20aa b-catenin binding repeats three short recognition
motifs, composed of the highly conserved LxECIxSAMP
sequence (called SAMP motif), constitute binding sites
for Axin [17-19]. The remarkably large number of b-
catenin binding sites in the APC protein has instigated
an area of intense research to search for the mechanistic
role of the APC b-catenin binding repeats in the
destruction complex.
Each 15aa repeat of APC binds to the structural
groove formed by the armadillo repeats 5-10 on the sur-
face of b-catenin in a phosphorylation-independent
Figure 1 The human APC protein carries a large predicted disordered domain which is frequently hit by missense mutations in
cancer. (A) Schematic representation of the APC scaffold protein and its protein interaction domains. Known interactors are APC (green), CRM1
(orange), PP2A (brown), b-catenin, CtBP (15aa repeats, blue), b-catenin (20 aa repeats, cyan), sequence B (yellow), Axin (SAMP-repeats, purple),
Microtubules (dark green) and EB1 (light green). (B) Summary of disorder predictions performed for full-length human APC using different
algorithms from publicly available servers [31-35]. Sequence segments with disorder probability above 50% are represented as black bars. (C)
Distribution of missense mutations in the APC protein reported in various tumors, categorized as somatic (red), germline (black) or unknown
origin (grey). Details on the location and nature of amino acid substitutions can be found in additional file 1, Table S1. (D) Summary of disorder
predictions performed for b-catenin (black bars), done as in (B), and b-catenins’s helical secondary structure elements as determined by
crystallography (gray bars) [36].
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of a consensus SXXSSLSXLS motif to convert into tight
binding sites for b-catenin [20,21]. In addition, two
negatively charged residues in the N-terminal flanking
regions of the core 20aa repeats make significant contact
with b-catenin by forming 2 salt bridges with K435 and
K312 of b-catenin [20,21]. Once bound, one single phos-
phorylated 20aa repeat plus N-terminal flanking
sequence of APC occupies almost the entire groove that
spans from armadillo repeats 1 to 12 on the b-catenin
surface. The bound conformation of one extended 20aa
repeat is nearly identical to that of other functional
binding partners of b-catenin, TCF [22] and E-cadherin
[23], indicating that these proteins cannot bind b-cate-
nin simultaneously.
Unlike their equal organization in binding motifs, indi-
vidual 15aa and 20aa repeats in APC vary considerably
in their binding affinities for b-catenin, with the tightest
binding site being the phosphorylated third 20aa repeat
(Kd 1.5 nM) [24]. Remarkably, the highly conserved sec-
ond 20aa repeat completely lacks binding affinity for b-
catenin, even in the phosphorylated state, likely due to
the absence of some of the conserved residues in the N-
terminal region flanking the core 20aa sequence. Phos-
phorylated APC competes with Axin for binding to b-
catenin, whereas unphosphorylated does not [21,25].
Based on these findings, various models have been pro-
posed on the mechanism by which phosphorylation of
the 20aa repeats in APC may regulate b-catenin recruit-
ment and turnover. In a first model, both the 15aa
repeats of APC and the b-catenin binding domain in
Axin bind b-catenin side by side to induce b-catenin
phosphorylation by GSK3b. As soon as the third 20aa
repeat of APC is phosphorylated it will bind phospho-b-
catenin thereby releasing Axin from the complex
[21,24]. This would facilitate the discharge and degrada-
tion of phospho-b-catenin and allow a new phosphoryla-
tion cycle to occur. In a second model, b-catenin first
binds phosphorylated APC with high affinity. Subse-
quent dephosphorylation of APC is then required to
weaken the interaction between APC and b-catenin,
allowing transfer of b-catenin to Axin and phosphoryla-
tion by Axin-associated GSK3b [1]. This model is
opposed by recent findings that demonstrate a crucial
role of APC in protecting phosho-b-catenin from
dephosphorylation by PP2A [26]. As a consequence,
APC would stay tethered to phospho-b-catenin and
directly deliver it to the E3 ligase b-TrCP for ubiquitina-
tion. In a third model, phosphorylation of APC accom-
modates the fluctuation in b-catenin levels in the cell in
conditions of presence versus absence of a Wnt signal.
During active Wnt signaling, abundant levels of b-cate-
nin will be dealt with by rapid and transient interactions
between b-catenin and nonphosphorylated APC. In the
absence of a Wnt signal, low levels of b-catenin will be
tightly bound and slowly released by phosphorylated
APC [21,27].
Each of the above models were challenged by a recent
s t u d yi nw h i c ht h er o l e so ft h e2 0 a aa n d1 5 a ar e p e a t s
were addressed systematically through the functional
analysis of a large number of APC variants in human
cells and flies [28]. Importantly, separate roles of APC
in the cytoplasmic retention and destruction of b-cate-
nin were uncovered, involving selective APC regions.
The affinities of individual b-catenin binding repeats in
APC were uncovered to be of lesser importance in the
destruction of b-catenin than anticipated in previous
models. Instead, the b-catenin binding repeats act in
concert to mediate retention of the b-catenin protein in
the cytoplasm, thus preventing its activity in the
nucleus. Strikingly, the second 20aa repeat which lacks
affinity for b-catenin, as well as the conserved sequence
B/CID, located in between the second and third 20aa
repeat (Figure 1A) [28,29], perform critical roles in the
APC-mediated destruction of b-catenin. How these
regions control APC activity and whether this involves
binding of co-factors remains to be solved.
Further experiments are needed to demonstrate if the
repeat regions act simultaneously or sequentially and
determine how these events are regulated by APC phos-
phorylation as well as by the second 20aa repeat and
sequence B in the process of b-catenin destruction.
The central domain of APC is intrinsically disordered
Strikingly, APC lacks sequence conservation outside the
small repetitive b-catenin- and axin-binding regions and
sequence B. This led us to investigate the structural
properties of APC in more detail using nine established
algorithms to predict secondary structure and disorder.
Each of the algorithms consistently indicate the presence
of an exceptionally large intrinsically disordered region
from F800 to V2843 in APC (Figure 1B) [30-35], yield-
ing a stretch of 2000 residues with an extended, flexible
conformation (Figure 2). The reliability of those algo-
rithms is well established as illustrated using b-catenin
and Axin as example proteins, for which we can com-
pare bioinformatics results with the experimentally veri-
fied structure (Figure 1D) [36,37]. The disorder
prediction algorithms for b-catenin confirm unfolded N-
and C-terminal segments flanking the folded, helical
core of the protein. Indeed, for these regions crystallo-
graphic studies failed to detect regular structure [36].
For the Wnt pathway tumor suppressor Axin, we
experimentally confirmed the intrinsically disordered
nature of the functionally important central region, thus
confirming the predictions derived of various algorithms
[37]. The prediction data for APC are supported by Far-
UV CD spectra and NMR studies on various purified
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acting 15aa and 20aa repeat regions in the unbound
state [24]. In addition, the middle and C-terminal
regions of APC, but not its N-terminus, were sensitive
to proteolytic degradation, confirming a lack of globular
domains in this part of the protein [38]. While short
disordered sequences are common features in human
proteins, such as e. g. activation loops in kinases, a con-
tinous stretch of 2000 amino acids length is rather
unique in the human proteome.
Intrinsically disordered regions in proteins are rapidly
gaining interest because of their intimate connection to
signaling networks and their growing link to human dis-
ease [39]. Disordered regions of over 30 residues in
length are 5- to 15-fold enriched in higher eukaryotic
proteomes (30%) relative to eubacteria (6%) and archaea
(2%), respectively [40,41], which is believed to reflect the
use of disordered domains in higher order eukaryotic
signaling networks. Moreover, 79% of cancer-associated
proteins contain disordered regions of 30 residues or
longer [42]. Among these are key tumor suppressor pro-
teins like p53, Axin, BRCA1 and the pro-apoptotic pro-
tein ASPP2 [37,39,43].
What could be the functional advantage of such a
long, extended, unstructured region for APC? Strikingly,
intrinsically disordered regions are often strongly modi-
fied by e.g. phosphorylation or acetylation, which implies
a relation between their dynamic appearance and regula-
tion by posttranslational modification [44]. Indeed, such
modifications can fine-tune protein-protein interactions
and activity of the protein complex [24,45]. Another
aspect of the extended nature of intrinsically disordered
domains are simultaneous interactions with multiple
binding partners with high specificity. For BRCA1, the
breast cancer tumor suppressor protein, over 50 binding
partners were reported, the majority of which bind to
the unstructured central domain [42]. In remarkable
contrast to BRCA1 and other disordered proteins, the
unstructured central domain of APC mainly provides
repetitive binding sites for two Wnt pathway binding
partners, b-catenin and Axin.
A possible reason for this unusual property of APC
might be related to the tight regulation of its activities.
The main function of the central domain of APC is to
downregulate cytoplasmic b-catenin levels with the
assistance of Axin and its associated kinases CK1 and
GSK3b. We propose that the long, flexible conformation
of APC helps to sift through the cytoplasm for b-catenin
substrate. The possibility to capture a b-catenin mole-
cule is enhanced by large contact surface created by the
extended peptide repeats that may allow one APC mole-
cule to bind up to ten b-catenin molecules in the phos-
phorylated state (Figure 1), using four 15aa and six
functional 20aa repeats. The presence of several binding
sites, some of which are regulated, controls affinity for
b-catenin by an avidity effect. This effect is further
increased by dimerization of APC.
Disordered proteins occupy a significantly larger
volume than folded proteins [46]. Assuming that the
conformational ensemble of APC was random, the 2000
disordered C-terminal APC residues would occupy the
volume of a particle with a diameter of 45 nm. This can
be calculated based on the experimentally determined
radius of gyration for disordered proteins [47], multi-
plied with square root of 6 [48]. Disordered proteins,
however, differ from folded proteins by being able to
easily adapt their shape to external influence. The struc-
tural flexibility can be illustrated by a gedankenexperi-
ment: assuming that the backbone of one amino acid
covers 3 Å in a fully extended conformation, 2000
Figure 2 Structural organization of the largely unfolded human APC protein. Scaled representation of APC as a large and highly flexible
protein with only a few folded segments located at its N-terminus. Folded domains, extended regions and their binding partners are indicated
with a color code as in Figure 1. The extended conformation of the predicted disordered domain (F800 - V2843) is reflected by the increased
protein length per amino acid residue. The relative scale indicates the maximally possible length of fully extended APC. For comparison of
protein compactness, a schematic representation of the tightly folded Armadillo repeat domains of b-catenin (spanning 510 residues, comprising
10 nm only, dark blue rectangle) is depicted to scale.
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μm when forced to do so. Its extended structure would
place APC among the longest non-polymeric proteins
located to the cytosol. Stretching of APC can be
enforced e.g. binding to cofactors. Indeed, b-catenin was
found to significantly extend the part of APC that is
bound to it [21]. Extrapolation from the conformation
exhibited by the disordered APC fragment in complex
with b-catenin as it was found by X-Ray crystallography
[21], would stretch APC to around 0.2 μm. In compari-
son, the folded 510 amino acid long armadillo repeat
region of b-catenin, which also exhibits an extended
s t r u c t u r e ,i sf i x e da tad e f i n e dl e n g t ho fj u s ta b o u t1 0
nm (Figure 2). The actual length of APC is most likely
between those extremes and might be modulated by its
interaction partners.
Disorder secures specificity of complex formation
In several reported cases, binding of interacting proteins
induces (partial) folding or secondary structure forma-
tion of disordered regions [42,49,50]. Templates for
folding include other proteins, nucleic acids, mem-
branes, or small molecules. The conformation that is
adopted by one intrinsically disordered region may differ
significantly depending on the binding partner. Thus,
disordered domains may provide significant binding
plasticity. Therefore, disordered sequences are enriched
in signaling proteins such as APC that are part of com-
plex protein interaction networks [42].
Alternatively, the disordered regions of APC may not
undergo significant conformational changes but instead
remain in extended conformation to provide in abun-
dant and transient contacts with their binding partners.
As binding of a disordered protein to a partner
restricts its dynamics, the interaction will involve an
entropic penalty, which folded proteins do not pay
[49]. As a result, disordered proteins can display highly
specific interactions of relatively low affinity as com-
pared to protein-protein interactions involving folded
proteins [51]. These interactions frequently depend on
electrostatic interactions tuned by posttranslational
modifications (e.g. phosphorylation) that create
changes in net charge of the binding regions [51,52].
Crystal structures obtained from short APC peptide
fragments in complex with b-catenin [13] reveal that
the phosphorylated 20aa peptide of APC does not
acquire structure but remains largely extended while
bound to b-catenin. The extended conformation allows
merely 15 residues of APC (A1485-G1499) to bind to
t h ee n t i r eg r o o v eo nt h eb-catenin Arm repeat surface
[21]. In contrast, the SAMP repeat segments, predicted
to lack secondary structure in the unbound state,
adopt a helical conformation upon binding to the Axin
RGS domain [53]. Clearly, the central domain of APC
uses different binding modes in its interaction with b-
catenin and Axin.
How may APC exploit the properties of its unstruc-
tured domains and secure specificity of their function?
Like many other scaffolding proteins, APC acts in multi-
ple independent cellular pathways at different subcellu-
lar locations and within different protein complexes. If
conformation of an unstructured domain depends on its
binding partners the protein will mold to adjust to the
pathway in which it functions together with signaling
partners in the complex. Moreover, it can be envisioned
that allosteric mechanisms propagate structure or sig-
nals to flanking domains [42,54,55], further enforcing
this functionally adoptive mechanism by determining
which distant binding partners are allowed to join in the
protein complex. To what extend such molecular
mechanisms apply for APC remains to be determined.
Mutations in APC cause cancer
T h ef a c tt h a tm u t a t i o n si nAPC strongly predispose to
colon cancer is well established [4,56]. Individuals carry-
ing a truncating APC allele suffer from familial adenoma-
tous polyposis (FAP), an autosomal dominant disorder
characterized by hundreds to thousands of colorectal
adenomas, some of which progress to cancer [57-59].
Moreover, mutations in APC are found in around 80% of
sporadic colonic tumors [60]. The molecular events in
FAP patients are phenocopied in the small intestine of
mouse models in which APC is truncated after the N-
terminal Armadillo repeat region, thus lacking domains
involved in b-catenin downregulation [56]. The high fre-
quency of gastro-intestinal tumor formation in these
mice results from loss of the wild-type allele (LOH) and
the following stabilization and accumulation of transcrip-
tionally active nuclear b-catenin [7,8].
APC does not, however, act as a classical tumor sup-
pressor. Careful comparison of mutations in both Apc
alleles in tumors, levels of Wnt signaling and severity of
disease in both humans and mice has led to a model in
which gene dosage effects generate a defined window of
enhanced Wnt signaling which leads to polyp formation
in the intestine. Combinations of ‘milder’ Apc mutations,
associated with weaker enhancement of Wnt signaling,
rather lead to tumors in extra-intestinal tissues [61,62].
In this model, the nature of the germline mutation in
Apc determines the type of somatic mutation mutation
that occurs in the second allele. As a consequence, the
resulting Wnt pathway activity is ‘just right’ for tumor
formation [56,63].
The main focus of research in this area has been on
the effects of truncating mutations in Apc.I nt h e s e
cases, large portions of the protein, including defined
regulatory domains, are lost. Recent studies, using opti-
mized technology to identify base pair alterations,
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germline as well as sporadic single amino acid substitu-
tions (missense mutations) in Apc predispose to devel-
opment of colorectal adenomas [64]. Notably, a
significant number of APC missense mutations were
reported in tumors originating from various tissues
(listed in additional file 1, Table S1, including references
therein). Moreover, missense mutations in APC were
linked to worse disease outcome in invasive urothelial
carcinomas [65], suggesting functional relevance of
point mutated APC protein in the development of
extra-intestinal tumors. Most of these mutations remain
functionally uncharacterized although for some missense
mutant APC proteins Wnt signaling activating proper-
ties were demonstrated [66]. The molecular basis by
which these mutations interfere with the function of
APC remains unresolved.
Molecular consequences of missense mutations in the
disordered domain of APC
Long, unstructured regions a r el i k e l ym o r ea p tt or e s i s t
the effects of point mutations than a folded protein. In
the large disordered region of APC, mutational resistance
is expected to be further enhanced by multiplication of
important interaction sites for partner proteins. A large
number of germline and somatic missense mutations in
APC however link to various forms of cancer and are
identified in a scattered pattern throughout the APC pro-
tein (Figure 1C and additional file 1, Table S1). More-
over, the somatic missense mutation frequency is
strongly enriched in the central Wnt regulatory MCR
region that is also frequently hit by truncating mutations.
Of note, the increased frequency in missense mutations
could be the result of the sequencing bias of many stu-
dies in which the MCR region was selectively sequenced
to identify mutations in APC. Remarkably, the majority
of reported missense mutations in APC MCR are located
o u t s i d et h ee s s e n t i a l1 5 a aa n d2 0 a ar e p e a tr e g i o n sa n d
their flanking N-terminal regions required for binding b-
catenin (Figure 3 and additional file 1, Table S1). How
can these seemingly subtle changes in an unstructured
domain have such dramatic consequences? We propose






























Mutation cluster region (MCR)
Figure 3 Missense mutations cluster outside the b-catenin binding motifs in the MCR of APC. (A) Closeup on missense mutation
frequency in MCR. Color code as in Figure 1C. (B) Domain structure of the MCR, color code as in Figure 1A. We calculated mutation frequency
by dividing the number of mutations in a particular codon by the total number of missense mutations reported in all referenced studies.
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reported missense mutations change side chain charges
which might have direct implications for the formation
of protein-protein interaction interfaces (additional file
1, Table S1) [66]. The single known binding partner of
the MCR region is b-catenin but, surprisingly, most of
the cancer-related mutations are outside the b-catenin
binding repeats. Possibly, the mutated residues belong
to non-redundant, so far unknown protein-protein inter-
action sites, although the lower conservation of these
regions would render this option less likely.
(ii) Changes in secondary structure formation. Mis-
sense mutations may alter the ability of APC to adopt
structure when bound to its interaction partners in the
destruction complex. This would be of importance for
local helix formation of APC SAMP-repeat regions
upon binding Axin. Indeed, missense mutations that
locate to these regions and introduce residues that
reduce helix stability (Gly, Val) were reported as germ-
line mutations in cases of adenomatous polyposis coli
(Figure 3 and additional file 1, Table S1) [66-68].
(iii) Posttranslational modifications. Point mutations
may interfere with posttranslational modifications of
APC. For instance, mutations in APC may alter recogni-
tion sites for responsible kinases such as CK1 and
GSK3b. These kinases do not directly dock onto APC
but rather are positioned towards their substrate resi-
dues by binding to Axin in the complex [69]. Mutations
within close proximity of target Ser residues in the 20aa
repeats may interfere with phosphorylation of these
motifs. Alternatively, mutations may hamper the pro-
tecting function of APC towards PP2A-mediated depho-
sphorylation of phospho-b-catenin and/or the delivery
of b-catenin to b-TrCP [26]. Interference with this role
of APC may lead to rapid dephosphorylation and stabili-
zation of b-catenin. It is currently unknown what
regions of APC are involved in these consecutive steps
in b-catenin degradation and whether or not this
requires extended or folded APC configuration. This
information will be essential to determine whether mis-
sense mutations may interfere with this function of
APC.
(iv) Dynamics of conformational equilibrium. Natively
unfolded sequences may adopt a specific three dimen-
sional conformation upon binding of a partner protein
[70]. This may include a specific spatial arrangement of
the repeat regions in APC. Point mutations outside
those regions could prevent the required formation of a
specific three-dimensional structure and, thereby, inhibit
APC’s usual mode of action. Hypothetically, mutations
may also influence long-range intramolecular signaling.
Examples of allosteric regulation of protein signaling are
rapidly emerging [71]. Binding to or modification of one
end of an protein elicits a signal that is communicated
through the protein to trigger a response at a remote
site, although it would be less obvious how such signal
transmission may work in an unfolded segment.
If and how these mechanisms may play a role in the
tumor suppressor activity of APC remains to be deter-
mined. It is obvious that the classical paradigms
obtained for folded proteins fail to explain the pheno-
type of APC cancer mutations. We consider it likely
that the effect is related to the dynamic nature of the
disordered regions of APC. In that respect the recent
discovery of the conserved sequence B as a critical func-
tional APC unit is of interest [28,29]. Obviously,
sequence B activity may involve binding partners that
remain to be discovered. Alternatively, alterations in
sequence B may simply disturb the dynamic interplay of
the b-catenin binding repeats or modulate the competi-
tion with Axin for b-catenin binding. The importance of
disordered regions is a newly emerging field, and its
unusually large disordered stretch make APC a key
paradigm to understand the role of unfolded regions in
general.
Conclusions and perspectives
Current mechanistic models of APC tumor suppressor
function leave many questions as to how APC coordi-
nates b-catenin degradation. Through its various
domains, APC is able to interact with many different
proteins. Multiple repeat regions for interaction with
both b-catenin and Axin are implicated in its tumor
suppressor activity. Structural information about how
these proteins are positioned within the b-catenin
destruction complex is lacking. Remarkably, the large
central domain of APC, spanning over 2000 amino acids
and carrying the repeat regions involved in b-catenin
downregulation, is predicted to be entirely unstructured.
T h i sf e a t u r ei sr a t h e ru n i q u ei nt h eh u m a ng e n o m ea s
only a few other proteins in the human proteome carry
similarly sized unfolded domains. Combined structural
and functional analysis of the unstructured domains of
APC will be needed to reveal if structure is acquired
upon binding to partner proteins. Answers as to how
APC missense mutations contribute to tumorigenesis
remains to be uncovered by studying how selected
tumor-associated mutationsi n t e r f e r ew i t he s s e n t i a l
tumor suppression mechanisms of APC.
Additional material
Additional file 1: Table S1. Germline and somatic missense
mutations in APC reported in human cancer. List of APC missense
mutations reported in human tumors. Mutated amino acid residue,
affected codon, tumor type, germline or somatic nature of the mutations
and corresponding references are indicated. Nucleotide numbering
reflects cDNA numbering with +1 corresponding to the A of the ATG
translation initiation codon in the reference sequence (Genbank
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Page 7 of 9NM_000038.4). The translation initiation codon is codon 1 (Genbank
NP_000029). ND = Not described. *In these studies, healthy tissue was
used as control.
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